Northern Trust’s Arcus Biosciences RCUS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $18.2M | Buy |
840,305
+45,507
| +6% | +$983K | ﹤0.01% | 1737 |
|
|
2025
Q4 | $18.9M | Buy |
794,798
+87,002
| +12% | +$1.78M | ﹤0.01% | 1701 |
|
|
2025
Q3 | $9.63M | Buy |
707,796
+16,549
| +2% | +$172K | ﹤0.01% | 2130 |
|
|
2025
Q2 | $5.63M | Buy |
691,247
+121,205
| +21% | +$1.04M | ﹤0.01% | 2404 |
|
|
2025
Q1 | $4.47M | Buy |
570,042
+37,943
| +7% | +$440K | ﹤0.01% | 2481 |
|
|
2024
Q4 | $7.92M | Buy |
532,099
+22,181
| +4% | +$362K | ﹤0.01% | 2260 |
|
|
2024
Q3 | $7.8M | Buy |
509,918
+8,485
| +2% | +$134K | ﹤0.01% | 2214 |
|
|
2024
Q2 | $7.64M | Sell |
501,433
-12,065
| -2% | -$195K | ﹤0.01% | 2151 |
|
|
2024
Q1 | $9.69M | Sell |
513,498
-11,191
| -2% | -$194K | ﹤0.01% | 2065 |
|
|
2023
Q4 | $10M | Buy |
524,689
+7,205
| +1% | +$115K | ﹤0.01% | 2069 |
|
|
2023
Q3 | $9.29M | Buy |
517,484
+10,169
| +2% | +$204K | ﹤0.01% | 2059 |
|
|
2023
Q2 | $10.3M | Sell |
507,315
-23,660
| -4% | -$451K | ﹤0.01% | 2042 |
|
|
2023
Q1 | $9.68M | Sell |
530,975
-179,647
| -25% | -$3.43M | ﹤0.01% | 2039 |
|
|
2022
Q4 | $14.7M | Buy |
710,622
+17,614
| +3% | +$485K | ﹤0.01% | 1744 |
|
|
2022
Q3 | $18.1M | Buy |
693,008
+11,458
| +2% | +$303K | ﹤0.01% | 1558 |
|
|
2022
Q2 | $17.3M | Buy |
681,550
+81,142
| +14% | +$1.99M | ﹤0.01% | 1635 |
|
|
2022
Q1 | $18.9M | Sell |
600,408
-23,862
| -4% | -$800K | ﹤0.01% | 1718 |
|
|
2021
Q4 | $25.3M | Sell |
624,270
-15,962
| -2% | -$619K | ﹤0.01% | 1608 |
|
|
2021
Q3 | $22.3M | Sell |
640,232
-27,949
| -4% | -$870K | ﹤0.01% | 1723 |
|
|
2021
Q2 | $18.3M | Buy |
668,181
+167,335
| +33% | +$4.78M | ﹤0.01% | 1946 |
|
|
2021
Q1 | $14.1M | Sell |
500,846
-34,719
| -6% | -$1.21M | ﹤0.01% | 2065 |
|
|
2020
Q4 | $13.9M | Sell |
535,565
-16,883
| -3% | -$409K | ﹤0.01% | 2044 |
|
|
2020
Q3 | $9.47M | Buy |
552,448
+65,365
| +13% | +$1.46M | ﹤0.01% | 2138 |
|
|
2020
Q2 | $12.1M | Buy |
487,083
+85,252
| +21% | +$2.3M | ﹤0.01% | 1988 |
|
|
2020
Q1 | $5.58M | Buy |
401,831
+14,964
| +4% | +$186K | ﹤0.01% | 2234 |
|
|
2019
Q4 | $3.91M | Buy |
386,867
+23,045
| +6% | +$194K | ﹤0.01% | 2732 |
|
|
2019
Q3 | $3.31M | Buy |
363,822
+31,566
| +10% | +$254K | ﹤0.01% | 2802 |
|
|
2019
Q2 | $2.64M | Buy |
332,256
+18,696
| +6% | +$187K | ﹤0.01% | 2916 |
|
|
2019
Q1 | $3.92M | Buy |
313,560
+10,451
| +3% | +$113K | ﹤0.01% | 2698 |
|
|
2018
Q4 | $3.27M | Buy |
303,109
+199,175
| +192% | +$2.32M | ﹤0.01% | 2764 |
|
|
2018
Q3 | $1.45M | Buy |
103,934
+40,735
| +64% | +$519K | ﹤0.01% | 3363 |
|
|
2018
Q2 | $774K | Buy |
+63,199
| New | +$992K | ﹤0.01% | 3504 |
|
Other funds holding RCUS
GS
SCM
VPM
VCM
WP
SL
Northern Trust's RCUS Position: Q1 2026 in Review
Northern Trust increased its Arcus Biosciences (RCUS) stake by 5.7% in Q1 2026, buying an estimated $983K and bringing the position to 840,305 shares worth $18.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1737.
Northern Trust first reported a position in RCUS in Q2 2018 and has held it in 32 quarters since. The position peaked at $25.3M in Q4 2021. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.
- Northern Trust held 840,305 shares of Arcus Biosciences worth $18.2M as of Q1 2026.
- Northern Trust bought 45,507 Arcus Biosciences shares in Q1 2026, an estimated $983K.
- Arcus Biosciences made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #1737 holding.
- Northern Trust first reported a position in Arcus Biosciences in Q2 2018 and has held it in 32 quarters since.
- Northern Trust's Arcus Biosciences position peaked at $25.3M in Q4 2021.
- 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.
Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.